Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
Claudio Laudani, Former Postdoctoral Researcher at UF Health Jacksonville, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Anti-inflammatory therapies are increasingly recognized as key tools to reduce major adverse cardiovascular events (MACE) in patients with coronary artery disease (CAD). Among them, colchicine has the most established and widely studied role in this setting.
However, the recent findings from clear-synergy have raised important questions regarding the efficacy and safety of colchicine for secondary prevention in CAD.
To address these uncertainties, we conducted the largest meta-analysis on colchicine to date, including 20 randomized controlled trials and 21,486 patients. We explored possible sources of heterogeneity and the influence of confounders, including clinical presentation (acute or chronic coronary syndrome), baseline medications, and the influence of colchicine dose administered, and COVID-19 pandemic. In addition, we performed trial sequential analysis to assess the conclusiveness of the results.
Overall, colchicine reduced MACE by 29%, driven by a 19% reduction in myocardial infarction and 30% reduction in revascularization, without inreasing serious adverse events. These resulted in a number needed to treat of 49 patients, and a NNT/NNH ratio of 0.5. Importantly, no significant interaction by presentation was detected, suggesting that both ACS and CCS patients may benefit from colchicine adminsitration.
However, there was a significant increase in gastrointestinal adverse events, which should be accounted when considering adding colchicine for secondary prevention of MACE, and adverse events were more likely to occur with high dose colchicine, suggesting that low-dose colchicine may achieve the best benefit/risk balance.
Finally, among possible confounders, only the COVID pandemic resulted as a possible explanation for the neutral results reported in the clear-synergy trial. Interestingly, TSA showed that results were conclusive for MACE and gastrointestinal events, further reassuring on the overall efficacy and safety of this medication for treatment of patients with CAD.”
Title: Safety and Efficacy of Colchicine across the Spectrum of Coronary Artery Disease: A Systematic Review and Meta-Analysis of 20 Randomized Trials
Authors: Claudio Laudani, Kamil Bujak, Giovanni Occhipinti, Riccardo Rinaldi, Antonino Imbesi, Jorge Sanz Sanchez, Mattia Galli, Antonio Abbate, Luis Ortega-Paz, Davide Capodanno, Dominick Angiolillo
Read the Full Article on American Society for Clinical Pharmacology and Therapeutics.
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 15, 2026, 10:49Aurelio Maggio: How Is The Treatment Landscape Of Thrombotic Thrombocytopenic Purpura Evolving?
-
Jun 15, 2026, 10:49Marek Mráz: A Landmark EHA 2026 for Our Lab
-
Jun 15, 2026, 10:32Magnus Ek: Operational Excellence in Delivering Seamless Access for 17,000 Delegates at EHA 2026 Congress
-
Jun 15, 2026, 10:15Carol Bewick: Why the Global Community Makes EHA 2026 Unforgettable
-
Jun 15, 2026, 10:07Habib Bennaceur: Driving Haemoglobinopathies Progress Across Multiple Clinical Programmes At EHA 2026
-
Jun 14, 2026, 22:49Cihan Ay: From First Oral Presentation to Pro and Con Debate – A 20-Year EHA Journey
-
Jun 14, 2026, 19:54Tareq Abadl: What Happens If You Transfuse the Wrong Blood Group?
-
Jun 14, 2026, 19:46Amber Yates: Stretching Scientific Muscles in Areas of Hematology – Day 2 at EHA 2026
-
Jun 14, 2026, 19:41Peter Loffelhardt: Thousands of People Coming in – Second Day at EHA 2026